Psychedelics for Psych Conditions Made Their Mark in 2023
In January, we reported on an investigational psychedelic that alleviated symptoms of depression in a mid-stage trial. In this report, we follow up on what has happened since that study was published. In the phase IIa trial, an investigational N,N-dimethyltryptamine treatment — commonly known as the hallucinogen DMT — significantly reduced depressive symptoms by 7.4 […]
Novel Anti-HER2 Drugs ‘Impressive’ in Advanced Biliary Cancer
CHICAGO — In a pair of mid-stage trials, newer targeted therapies demonstrated meaningful levels of activity against HER2-positive biliary tract cancers in pretreated patients with advanced disease. Cohort 1 of the global HERIZON-BTC-01 study, which included 80 treatment-refractory patients, showed that 41.3% (95% CI 30.4-52.8) responded to zanidatamab, an investigational bispecific monoclonal antibody that targets […]